Orforglipron vs oral semaglutide
Orforglipron lowered HbA1c more than oral semaglutide in ACHIEVE-3, but gastrointestinal events were more frequent. That diabetes trial is not a Foundayo-versus-Wegovy weight-loss trial. For the US-labelled pills, another difference is daily use: Foundayo does not require fasting; Wegovy tablets do.
What did the head-to-head trial find?
ACHIEVE-3 randomised 1,698 adults with type 2 diabetes on metformin across four arms. This 52-week, open-label trial was funded by Lilly. The table selects the higher-dose arms; doses identify study groups, not a switching guide.
ACHIEVE-3: higher-dose arms
Swipe or scroll sideways to compare all columns.
| Outcome at 52 weeks | Orforglipron 36 mg | Oral semaglutide 14 mg |
|---|---|---|
| Study / population | ACHIEVE-3: adults with type 2 diabetes on metformin | Same trial population |
| Randomised participants | 423 | 425 |
| HbA1c change, percentage points | −1.91 | −1.47 |
| Gastrointestinal events | 58% | 45% |
| Stopped treatment because of adverse events | 10% | 5% |
What do these numbers mean?
HbA1c changes use the primary treatment-regimen analysis, including participants regardless of treatment interruptions. The adverse-event percentages describe these study arms; they are not individual risk predictions. This comparison does not test Wegovy’s obesity formulation.
Two pills, different instructions
Swipe or scroll sideways to compare all columns.
| Feature | Foundayo | Wegovy pill |
|---|---|---|
| Ingredient | Orforglipron | Semaglutide |
| Form | Oral tablet | Oral tablet |
| Food timing | Fasting is not required | Morning, empty stomach; wait at least 30 minutes afterwards |
| Weight-management indication | Adults meeting the labelled criteria | Adults meeting the labelled criteria |
| Other Wegovy formulation | Not applicable | A separate weekly injection is also labelled |
Why “Wegovy” alone is not enough
The Wegovy label lists both an injection and tablets. Their indications are not identical: for example, its injection weight-management indication includes eligible adolescents, while the tablet indication is for adults. A comparison that silently substitutes the injection for the pill answers a different question. Check the formulation as well as the brand.
What changes in the daily routine?
For Wegovy tablets, the label specifies an empty stomach in the morning, water only when taking the tablet, and a waiting period before food, drinks or other oral medicines. FDA’s Foundayo announcement says an empty stomach is not required. These are differences in labelled use, not a reason to switch products or transfer a dose between them.
Does the simpler schedule mean better results?
Food timing answers a practical question, not which medicine will produce more weight loss. Keep the product, formulation and study population attached to any comparison. ACHIEVE-3 answers a diabetes-treatment question; the US product instructions answer how the labelled pills differ in everyday use.
Use the table and its sources
Related reading
CompareRetatrutide vs tirzepatide
Tirzepatide targets GIP and GLP-1 receptors; retatrutide also targets the glucagon receptor.
ReadGLP-1 weight loss and muscle
Weight lost during GLP-1 treatment is not all fat.
ReadCreatine with GLP-1: the trial
Creatine during GLP-1 treatment is being tested directly.
ReadVitamins during GLP-1 treatment
There is no single vitamin stack in the joint nutrition advisory for everyone taking a GLP-1 medicine.
ReadGLP-1 treatment and hair shedding
Hair loss is reported in the Zepbound trials, and its label associates those reactions with weight reduction.
Source-linked editorial synthesis, prepared with AI assistance. This is not a clinician review or a personalised treatment recommendation. Corrections: editorial standards.